Hyperlipidemia in the elderly;Hyperlipidémies du sujet âgé

Presse Medicale

Volumn 30, Issue 19, 2001, Pages 957-963

  Farnier, M ^a  

^a Rond Point de la Nation ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; GEMFIBROZIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

AGED; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DEMENTIA; HEALTH STATUS; HUMAN; HYPERLIPIDEMIA; PROPHYLAXIS; REVIEW; STROKE;

AGED; AGING; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; DEMENTIA; EVIDENCE-BASED MEDICINE; HUMANS; HYPERLIPIDEMIAS; MASS SCREENING; RISK FACTORS;

EID: 0035954092     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Epidemiology of coronary heart disease in the elderly
2. Cardiovascular risk factors in the elderly
3. Age-related increase in mortality among patients with first myocardial infarctions treated with thrombolysis
4. Prevalence of chronic diseases in older Italians: Comparing self-reported and clinical diagnoses
5. Epidémiologie des accidents vasculaires cérébraux. D'après le registre dijonnais (1985-1988)
6. Clinical considerations regarding treatment of hypercholesterolemia in the elderly
7. Cholesterol and coronary heart disease in older adults. No easy answers
8. Lipoprotein alterations and atheroscleroris in the elderly
9. Cholestérolémie et mortalité totale, cardiovasculaire ou par cancer. Etude d'une cohorte de 220 000 personnes
10. Influence of age on the metabolism of plasma Low. Density Lipoproteins in healthy males
11. Regulation of serum cholesterol Level in middle-aged and elderly men. Relation of cholesterol absorption and synthesis to lipoprotein metabolism
12. Prevention of cardiovascular events in elderly hypercholesterolemic patients
13. The Cardiovascular Health Study. Epidemiology of low cholesterol levels in older adults
14. Clarifying the direct relation of total cholesterol with coronary heart disease mortality in older persons
15. Low serum cholesterol and mortality. Which is the cause and which is the effect?
16. Risk factors for 5-year mortality in older adults. The CardiovascuLar Health Study
17. Lipoprotein Lipids in older people. Results from the Cardiovascular Health Study
18. HDL-cholesterol predicts coronary heart disease mortality in older adults
19. High density lipoprotein cholesterol and risk of ischemic stroke mortality
20. Serum Lipids and Coronary heart Disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP)
21. Total and high density lipoprotein cholesterol as risk factors for coronary heart disease in elderly men during five years of follow-up: The Zutphen Elderly Study
22. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease
23. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
24. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
25. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
26. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS
27. Air Force/Texas Coronary Atherosclerosis Prevention Study: Extending the benefit of primary prevention to healthy elderly men and women
28. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Findings from the Scandinavian Simvastatin Survival Study (4S)
29. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrents Events (CARE) trial
30. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors
31. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
32. Reduction of stroke incidence after myocardial infarction with pravastatin. The cholesterol and recurrent events (CARE) study
33. Pravastatin therapy and the risk of stroke
34. Reduction of stroke events with pravastatin
35. Low-density lipoprotein-independent effects of statins
36. Statin trials in progress: Unanswered questions
37. The design of a prospective study of pravastatin in the elderly at risk (PROSPER)
38. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl Coenzyme A reductase inhibitors
39. Statins and the risk of dementia
40. Effects of Lovastatin on cognitive function and physiological well-being